Compounds > oxt-328
Page last updated: 2024-08-03 12:38:34

oxt-328

Description

OXT-328: a synthetic antineoplastic phospho-sulindac; structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID25181435
SCHEMBL ID11916853
SCHEMBL ID17165301
MeSH IDM0551024

Synonyms (6)

Synonym
oxt-328
SCHEMBL11916853
SCHEMBL17165301
1118973-90-2
cid 25181435
4-diethoxyphosphoryloxybutyl 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetate

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (92.86)24.3611
2020's1 (7.14)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
bis(4-nitrophenyl)phosphate
1
aryl phosphate2012201212.0low000010
aspirin
3
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		2011201511.3low000030
eflornithine
3
alpha-amino acid;
fluoroamino acid		trypanocidal drug2010201213.0low000120
valproic acid
1
branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent		2012201212.0low000010
ibuprofen
3
monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic		2011201511.3low000030
indomethacin
1
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		2012201212.0low000010
benzil
1
alpha-diketone;
aromatic ketone		2012201212.0low000010
phenylglyoxal
1
phenylacetaldehydes2012201212.0low000010
naproxen
1
methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		2012201212.0low000010
sulindac
14
monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent		2010202110.3high0001121
dinoprostone
3
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		2010201811.0low000120
cellulose
1
glycoside202120213.0low000001
nitrophenols
1
2012201212.0low000010
lactoferrin
1
201820186.0low000010
acetylcellulose
1
202120213.0low000001
concanavalin a
1
201820186.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Adjuvant Arthritis0
2
2011201312.0low000020
Bone Loss, Osteoclastic0
1
2013201311.0low000010
Breast Cancer0
1
2012201212.0low000010
Breast Neoplasms0
1
2012201212.0low000010
Cancer of Colon0
3
2010201213.0low000120
Cancer of Lung0
1
2012201212.0low000010
Cancer of Pancreas0
1
2014201410.0low000010
Cancer of Skin0
1
2012201212.0low000010
Cancer of Stomach0
1
2012201212.0low000010
Carcinoma, Epidermoid0
1
2012201212.0low000010
Carcinoma, Lewis Lung0
1
201520159.0low000010
Carcinoma, Squamous Cell0
1
2012201212.0low000010
Cell Transformation, Neoplastic0
1
2012201212.0low000010
Cholera Infantum0
1
2011201113.0low000010
Chronic Disease0
1
201820186.0low000010
Chronic Illness0
1
201820186.0low000010
Colonic Neoplasms0
3
2010201213.0low000120
Disease Models, Animal0
2
201320188.5low000020
Dry Eye0
2
201820214.5low000011
Dry Eye Syndromes0
2
201820214.5low000011
Inflammation0
1
2013201311.0low000010
Innate Inflammatory Response0
1
2013201311.0low000010
Lung Neoplasms0
1
2012201212.0low000010
Pancreatic Neoplasms0
1
2014201410.0low000010
Skin Neoplasms0
1
2012201212.0low000010
Stomach Neoplasms0
1
2012201212.0low000010

Safety/Toxicity (2)

ArticleYear
Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Pharmaceutical research, , Volume: 30, Issue:6		2013
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Gastroenterology, , Volume: 139, Issue:4		2010

Long-term Use (2)

ArticleYear
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Cancer prevention research (Philadelphia, Pa.), , Volume: 4, Issue:7		2011
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Gastroenterology, , Volume: 139, Issue:4		2010

Pharmacokinetics (2)

ArticleYear
The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
International journal of pharmaceutics, , Feb-25, Volume: 557		2019
The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
British journal of pharmacology, , Volume: 165, Issue:7		2012

Interactions (1)

ArticleYear
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Cancer prevention research (Philadelphia, Pa.), , Volume: 4, Issue:7		2011